COMPANY PROFILE / #3559
Ensocell
Cambridge, United KingdomVenture Capital-Backed
OVERVIEW
Developer of single-cell genomics technology intended to identify novel disease intervention points. The company specializes in utilizing AI-based computational tools and advanced cell models to discover novel therapeutics for autoimmune, inflammatory, and fibrotic diseases to decode the complexities of human disease biology, enabling researchers to provide regenerative therapies to fight diseases.
已融资16.32
最新估值21.87
员工数19
成立年份2023
公司概况
- Companies
- Ensocell
- Description
- Developer of single-cell genomics technology intended to identify novel disease intervention points. The company specializes in utilizing AI-based computational tools and advanced cell models to discover novel therapeutics for autoimmune, inflammatory, and fibrotic diseases to decode the complexities of human disease biology, enabling researchers to provide regenerative therapies to fight diseases.
- Website
- www.ensocell.com
- HQ Location
- Cambridge, United Kingdom
- Year Founded
- 2023
- Keywords
- autoimmune disease therapy, biotechnology research, fibrotic disease therapy, healthcare research, inflammatory disease, single cell genomics
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 16.32
- First Financing Date
- 19-Jul-2023
- First Financing Size
- 3.20
- First Financing Valuation
- 8.97
- Last Financing Date
- 24-Feb-2025
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 13.12
- Last Financing Valuation
- 21.87
- Last Financing Status
- Completed
- Last Known Valuation
- 21.87
- Last Known Valuation Date
- 24-Feb-2025
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 41.09
- Valuation Estimate Growth Rate
- 87.90%
- Active Investors
- OMX Ventures
- # Active Investors
- 1
- Acquirers
- —
团队与联系人
- Employees
- 19
- Employee Growth %
- -9.52%
- Employee History
- 2026: 19, 2025: 21, 2024: 16, 2023: 3
- Primary Contact
- Sarah Teichmann
- Primary Contact Title
- Co-Founder & Board Member
- Primary Contact Email
- sarah.teichmann@ensocell.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- -0.31%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 9
- Size Multiple
- 1.22x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 58
- Majestic Referring Domains
- 17
- SimilarWeb Unique Visitors
- 21
- SimilarWeb Unique Visitors Change
- -54
- SimilarWeb Growth Rate
- 0.00%
- SimilarWeb Growth Rate Percentile
- 9
- Success Probability Over Time – 1 Year
- 4%
- Success Probability Over Time – 3 Year
- 10%
- Success Probability Over Time – 5 Year
- 19%
记录来源：public.companies · 原始序号 #3559 · 所有字段均按数据库原值展示。